Biomedical Advanced Research and Development Authority
Overview
The Biomedical Advanced Research and Development Authority (BARDA) is a U.S. government entity within the Department of Health and Human Services (HHS) that supports the advanced development and procurement of medical countermeasures (MCMs) against chemical, biological, radiological, and nuclear (CBRN) threats, as well as pandemic influenza and emerging infectious diseases. BARDA acts as a bridge between the federal government and the biomedical industry, providing funding, technical assistance, and core services to partner companies to move products from research through advanced development and towards FDA approval. It utilizes public-private partnerships to accelerate the development of vaccines, drugs, diagnostics, and other necessary technologies for public health emergencies. BARDA also has a venture capital arm, BARDA Ventures, which it operates in partnership with the Global Health Investment Corporation (GHIC) to invest in innovative technologies.
Portfolio Companies
30
Website
hhs.govInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Visby Medical | Mar 2022 | Grant | Lead |
| Cytovale | Feb 2022 | Grant | Co-investor |
| Rivanna Medical | Jul 2025 | Debt | Lead |
| HDT Bio Corp. | Jan 2024 | Grant | Co-investor |
| SeLux Diagnostics | Sep 2018 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Biomedical Advanced Research and Development Authority based?
Biomedical Advanced Research and Development Authority is headquartered in District of Columbia.
When was Biomedical Advanced Research and Development Authority founded?
Founding year information for Biomedical Advanced Research and Development Authority is not publicly available.
How many portfolio companies does Biomedical Advanced Research and Development Authority have?
Biomedical Advanced Research and Development Authority has 30 portfolio companies in Caplight's dataset.
What are some companies in Biomedical Advanced Research and Development Authority's portfolio?
Portfolio companies visible on Caplight include Visby Medical, Cytovale, Rivanna Medical, HDT Bio Corp., SeLux Diagnostics.
What was Biomedical Advanced Research and Development Authority's most recent investment shown here?
Biomedical Advanced Research and Development Authority's most recent investment in this portfolio sample was in Rivanna Medical in 2025.
What sectors does Biomedical Advanced Research and Development Authority focus on?
Biomedical Advanced Research and Development Authority focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Cybersecurity, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Biomedical Advanced Research and Development Authority focus on?
Biomedical Advanced Research and Development Authority typically invests at the MultiStage stage.
What is Biomedical Advanced Research and Development Authority's AUM?
Biomedical Advanced Research and Development Authority's assets under management are estimated between $745.0M and $1.6B.